

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/526,507

Filed: 09/29/2005

1st Inventor: K. Hamamura

For: Furan or Thiophene Derivative and Medicinal Use Thereof

Atty. Dkt. No. 3092US0P

Art Unit: 1644

Examiner: tba

Allowed:

Batch:

Paper No.:

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10

USPS EXPRESS MAIL LABEL. No. EV 903172208 US

DATE IN: October 11, 2006

Itemized Papers/Items:


1. This Certificate and Return Postcard (2 pages)
2. Transmittal Form (1 page X 2)
3. Request to Correct Filing Receipt (1 page), and copy of Filing Receipt (1 page)

The undersigned hereby certifies that the above itemized papers are together being deposited with the Express Mail Post Office to Addressee service of the United States Postal Service (USPS) in an envelope with sufficient postage, having the USPS Express Mail Label No. shown above, and addressed to:


MAIL STOP MISSING PARTS
Commissioner for Patents
P.O. BOX 1450
Alexandria, VA 22313-1450

on this date, 10/11/06

Dated: 10/11/06


Gail L. Winokur

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
One Takeda Parkway
Deerfield, IL 60015 USA

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

6

Application Number

10/526,507

Filing Date

09/29/2005

First Named Inventor

K. Hamamura

Art Unit

1644

Examiner Name

tba

Attorney Docket Number

3092US0P

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Return Postcard;
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	Certificate of Express Mailing;
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	Request to Correct Filing Receipt
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	<input type="checkbox"/> Landscape Table on CD	Copy of Filing Receipt
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

Remarks

The Commissioner is authorized to charge any appropriate fees or credit any overpayment to Applicant's USPTO Deposit Account No. 500799.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name

Signature

Printed name

Mark Chao, Ph.D., JD

Date

Reg. No.

37,293

CERTIFICATE OF TRANSMISSION/MAILINGI hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Express

Signature

Typed or printed name

Gail L. Winokur


Date

10/11/2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Express Mail # EV 903 172 208 US



10-12-06

Receipt
Fru

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:	10/526,507	Art Unit:	1644
Filed:	09/29/2005	Examiner:	tba
1 st Inventor:	K. Hamamura	Allowed:	
For:	Furan or Thiophene Derivative and Medicinal Use Thereof	Batch:	
Atty. Dkt. No.	3092US0P	Paper No.:	

REQUEST FOR CORRECTED FILING RECEIPT

MAIL STOP MISSING PARTS
Commissioner for Patents
P.O. BOX 1450
Alexandria, VA. 22313-1450

Sir:

Applicants request that a corrected Filing Receipt be issued for the above-identified case correcting the "Assignment For Published Patent Application".

Please correct under "Assignment For Published Patent Application", as follows:

--TAKEDA PHARMACEUTICAL COMPANY LIMITED--

A copy of the Filing Receipt is enclosed showing the correction.

If there are any questions, please call applicants' attorney at (224) 554-5494.

Dated:


10/11/06

Respectfully submitted,

(224) 554-5494
(224) 554-5689

Mark Chao, Ph.D., Reg. No. 37,293
Elaine M. Ramesh, Ph.D., Reg. No. 43,032
Attorney for Applicants
Customer No. 23115

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
One Takeda Parkway
Deerfield, IL 60015 USA




UNITED STATES PATENT AND TRADEMARK OFFICE

360

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/526,507	09/29/2005	1644	4230	3092 USOP		44	1

Mark Chao
Takeda Pharmaceuticals North America Inc
Intellectual Property Department
Suite 500 475 Half Day Road
Lincolnshire, IL 60069



CONFIRMATION NO. 4233

CORRECTED FILING RECEIPT



OC000000020082879

Date Mailed: 08/17/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Kazumasa Hamamura, Osaka, JAPAN;
Shigekazu Sasaki, Osaka, JAPAN;
Yuichiro Amano, Osaka, JAPAN;
Junichi Sakamoto, Osaka, JAPAN;
Kohji Fukatsu, Osaka, JAPAN;

Assignment For Published Patent Application

TAKEDA PHARMACEUTICAL COMPANY LIMITED [INTELLECTUAL PROPERTY
DEPARTMENT], OSAKA, JAPAN

Power of Attorney:

Mark Chao-37293
Elaine Ramesh-43032

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/JP03/11308 09/04/2003

Foreign Applications

JAPAN 2002-261873 09/06/2002
JAPAN 2003-185241 06/27/2003

If Required, Foreign Filing License Granted: 03/27/2006

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US10/526,507**